Skip to main content

Table 1 Characteristics of patients at the time of medication initiation

From: The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis

  MTX All TNFi Anakinra MTX with SJIA
Number of patients 3075 2713 247 160
Mean age, years (SD) 9.0 (4.7) 10.9 (4.7) 9.4 (4.8) 7.4 (4.6)
Median age (IQR) 9.0 (5.0–13.0) 11.0 (7.0–15.0) 9.0 (6.0–13.0) 6.5 (3.0–11.0)
Female sex, % 66.0 68.3 64.4 56.9
Asthma, % 8.2 6.1 6.5 7.5
Diabetes mellitus, % 1.1 1.2 1.6 0.6
Psoriasis, % 2.7 3.9 0 8.8
Baseline oral GC dose, %
 None 67.1 57.5 22.3 40.0
 Low (<10 mg/day) 24.1 29.7 33.6 26.3
 High (≥10 mg/day) 8.8 12.9 44.1 33.8
MTX use on index date, % N/A 47.8 37.3 N/A
Cyclosporine use on index date, % 0.4 1.0 3.6 6.9
Baseline infection, %
 None 47.7 55.8 45.3 35.0
 Nonprimary hospitalized or outpatient 49.6 42.1 47.4 54.4
 Primary hospitalized 2.7 2.1 7.3 10.6
  1. Abbreviations: MTX Methotrexate, TNFi Tumor necrosis factor inhibitor, SJIA Systemic juvenile idiopathic arthritis, GC glucocorticoid, mg Milligrams of prednisone equivalent, N/A Not applicable
\